Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension

JAMA

Volumn 277, Issue 21, 1997, Pages 1689-1695

  Sechi, Leonardo A ^a,d   Kronenberg, Florian ^c   De Carli, Stefano ^a   Falleti, Edmondo ^b   Zingaro, Laura ^a   Catena, Cristiana ^a   Utermann, Gerd ^c   Bartoli, Ettore ^a  

^a Hypertension Unit   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; FIBRINOGEN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0030958352     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.21.1689     Document Type: Article

References (50)

1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
2. Kannel WB. Hypertension and the risk of cardiovascular disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990: 101-117.
3. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-910.
4. Berg K. A new serum type system in man - the Lp(a) system. Acta Pathol Microbiol Scand. 1963; 59:369-382.
5. Brunner C, Kraft HG, Utermann G, Muller HJ. Cys(4057) of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A. 1993;90:11643-11647.
6. Koschinsky ML, Cote GP, Gabel B, Van der Hoek YY. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem. 1993; 268:19819-19825.
7. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80: 458-465.
8. Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentrations. Hum Genet. 1992;90: 220-230.
9. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
10. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation: implications for apolipoprotein synthesis. J Clin Invest. 1989;83:137-142.
11. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J Clin Invest. 1980;65:1483-1490.
12. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in lipoprotein(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758-2763.
13. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins and the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.
14. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33:495-543.
15. Jauhiainen M, Koskinen P, Ehnholm C. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
16. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195-2199.
17. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest. 1990; 85:1709-1715.
18. Petrie JC, O'Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. BMJ. 1986;293:611-615.
19. Sechi LA, Melis A, Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism. 1992;11:1261-1266.
20. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. Hypertension. 1993;22:392-403.
21. Sahn DJ, Demaria A, Kisslo J, Weyman A, Committee of the M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58: 1072-1083.
22. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
23. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
24. Salonen R, Sappanen K, Ravramara R, Salonen JT. Prevalence of carotid atherosclerosis and serum cholesterol levels in Eastern Finland. Arteriosclerosis. 1988;8:788-792.
25. Scheie HG. Evaluation of ophthalmoscopic changes of hypertension and arteriolar sclerosis. Arch Ophthalmol. 1953;49:117-138.
26. Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem. 1972;18:499-502.
27. Rossi E, Lombardi A, Preda L. Method for determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res. 1988;52:453-468.
28. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis. 1996;125:53-61.
29. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Calif: Holden-Day; 1975.
30. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein (a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110-120.
31. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary artery disease: a study of six populations. Arterioscler Thromb. 1992; 12:1214-1226.
32. Molgaard J, Klausen IC, Lassvik C, Frgeman O, Gerdes LU, Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb. 1992;12:895-901.
33. Dahlen G, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Associations of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
34. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544-548.
35. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke. 1986; 17:942-945.
36. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993; 24:965-969.
37. Schreiner PJ, Morrisett JD, Sharrett AR, et al. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826-833.
38. Diekstall F, Canzler H, Schmidt E, Demeler U. Lipoprotein(a) bei arteriellen retinalen Gefabver-schlussen. Ophtalmologie. 1987;84:369-371.
39. Maioli M, Tonolo G, Pacifico A, et al. Raised serum apolipoprotein(a) in active diabetic retinopathy. Diabetologia. 1993;36:88-90.
40. Steinmetz A, Kirklies A, Schlosser G, et al. Lipoprotein(a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. Clin Invest. 1993;71:145-149.
41. Flesch M, Sachinidis A, Ko YD, Kraft K, Vetter H. Plasma lipids and lipoproteins and essential hypertension. Clin Invest. 1994;72:944-950.
42. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. 1996;27:1-25.
43. Rath M, Niendorf A, Reblin T, Dietel M, Kreber HJ, Beisiegel U. Detection and quantitation of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9: 579-592.
44. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
45. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risk associated with lipoprotein(a). Nature. 1989;339:301-302.
46. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
47. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1656.
48. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
49. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a): role of oxygen-derived radicals. Circulation. 1995;92: 1582-1589.
50. Tsurumi Y, Nagashima H, Ichikawa KL, Sumiyoshi T, Hosoda S. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine. J Am Coll Cardiol. 1995;26:1242-1250.